Metformin is backed as first line therapy for type 2 diabetes

The use of metformin as first line therapy for type 2 diabetes has been supported by a comprehensive systematic review and meta-analysis, given its relative safety and its beneficial effects on haemoglobin A_1c, weight, and cardiovascular mortality.1

The US research, published in the Annals of Internal Medicine, included 179 trials and 25 observational studies of head to head monotherapy or …